AGLE Aeglea BioTherapeutics, Inc. Stock Quote

AGLE [NASD]

Index	-	P/E	-	EPS (ttm)	-1.27	Insider Own	1.20%	Shs Outstand	49.31M	Perf Week	-7.64%
Market Cap	196.83M	Forward P/E	-	EPS next Y	-0.97	Insider Trans	98.67%	Shs Float	48.55M	Perf Month	-7.21%
Income	-68.10M	PEG	-	EPS next Q	-0.29	Inst Own	92.60%	Short Float	1.69%	Perf Quarter	-46.51%
Sales	15.10M	P/S	13.03	EPS this Y	38.10%	Inst Trans	1.08%	Short Ratio	2.39	Perf Half Y	-36.46%
Book/sh	2.07	P/B	1.93	EPS next Y	1.00%	ROA	-45.30%	Target Price	13.62	Perf Year	-40.98%
Cash/sh	2.28	P/C	1.75	EPS next 5Y	-	ROE	-56.20%	52W Range	3.47 - 8.79	Perf YTD	-16.00%
Dividend	-	P/FCF	-	EPS past 5Y	-8.50%	ROI	-	52W High	-54.61%	Beta	1.44
Dividend %	-	Quick Ratio	5.80	Sales past 5Y	-	Gross Margin	-	52W Low	14.99%	ATR	0.30
Employees	90	Current Ratio	5.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.63	Volatility	6.58% 6.86%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-42.20%	Profit Margin	-	Rel Volume	0.55	Prev Close	4.20
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 04 BMO	Payout	-	Avg Volume	344.38K	Price	3.99
Recom	2.10	SMA20	-9.52%	SMA50	-17.34%	SMA200	-39.64%	Volume	187,974	Change	-5.00%

May-04-20

Initiated

Piper Sandler

Overweight

$12

Mar-21-19

Initiated

JP Morgan

Overweight

$14

Sep-04-18

Downgrade

Wells Fargo

Outperform → Market Perform

Apr-24-18

Initiated

Evercore ISI

Outperform

$37

Mar-14-18

Reiterated

Needham

Buy

$8 → $12

Jan-25-22 08:01AM	Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency PR Newswire
Jan-05-22 07:01AM	Aeglea BioTherapeutics to Participate in Two Investor Conferences in January 2022 PR Newswire
Dec-17-21 06:14AM	3 Biotech Stocks That Sank: Are Any a Bad-News Buy? Motley Fool +14.41%
Dec-14-21 09:15AM	Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $198,982 of Shares GuruFocus.com
Dec-12-21 06:18AM	What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition Simply Wall St.
Dec-06-21 01:01PM	Why Aeglea BioTherapeutics Stock Is Way Down Today Motley Fool -36.50%
07:18AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday InvestorPlace
06:30AM	Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency PR Newswire
Dec-05-21 06:00PM	Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency PR Newswire
Nov-16-21 07:01AM	Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors PR Newswire
Nov-04-21 08:55AM	Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:01AM	Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights PR Newswire
06:59AM	Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics PR Newswire
Oct-19-21 06:26AM	Aeglea BioTherapeutics (NASDAQ:AGLE) shareholders have earned a 4.5% CAGR over the last five years Simply Wall St.
Sep-01-21 08:30AM	Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021 PR Newswire
Aug-10-21 01:00AM	Analysts Are Betting On Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) With A Big Upgrade This Week Simply Wall St.
Aug-08-21 03:06AM	Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates Simply Wall St.
Aug-07-21 03:14AM	Companies Like Aeglea BioTherapeutics (NASDAQ:AGLE) Are In A Position To Invest In Growth Simply Wall St.
Aug-05-21 10:05AM	Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Tops Revenue Estimates Zacks
08:30AM	Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights PR Newswire
Jul-26-21 11:50AM	Were Hedge Funds Right About Aeglea BioTherapeutics, Inc. (AGLE)? Insider Monkey
Jul-15-21 08:30AM	Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel PR Newswire
Jul-14-21 04:30PM	Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease PR Newswire
Jul-08-21 08:30AM	Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer PR Newswire
Jun-24-21 08:30AM	Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria PR Newswire +7.96%
Jun-22-21 08:30AM	Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors PR Newswire
May-10-21 08:30AM	Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights PR Newswire
May-06-21 08:30AM	Aeglea BioTherapeutics Launches THINK ARGININE, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency PR Newswire
May-03-21 08:30AM	Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire
Apr-01-21 04:30PM	Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021 PR Newswire
Mar-22-21 08:30AM	Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East PR Newswire +8.62%
Mar-18-21 08:30AM	Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights PR Newswire
Feb-24-21 04:30PM	Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors PR Newswire
Feb-18-21 01:45AM	We Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth Carefully Simply Wall St.
Feb-08-21 10:11AM	10 Best Small-Cap Biotech Stocks Under $10 in 2021 Insider Monkey
Feb-03-21 04:30PM	Aeglea BioTherapeutics Announces Transition of Chief Financial Officer PR Newswire
Jan-04-21 04:30PM	Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference PR Newswire +8.77%
Dec-30-20 12:00PM	Aeglea (AGLE) Upgraded to Buy: Here's Why Zacks
Dec-18-20 08:28PM	Is AGLE A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-17-20 04:05PM	Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors PR Newswire
Dec-01-20 07:30AM	Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria PR Newswire
Nov-24-20 04:40PM	Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference PR Newswire
Nov-17-20 04:30PM	Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences PR Newswire
Nov-10-20 05:40AM	How Much Are Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Spending On Buying Shares? Simply Wall St. +13.10%
Nov-05-20 08:30AM	Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights PR Newswire +8.08%
Nov-03-20 08:44AM	Is a Surprise Coming for Aeglea (AGLE) This Earnings Season? Zacks +5.68%
Oct-26-20 08:30AM	Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria PR Newswire -5.60%
Oct-13-20 12:35PM	Hedge Funds Are Crazy About Aeglea BioTherapeutics, Inc. (AGLE) Insider Monkey
Oct-05-20 04:30PM	Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings PR Newswire
Sep-11-20 06:39AM	Is Aeglea BioTherapeutics (NASDAQ:AGLE) In A Good Position To Invest In Growth? Simply Wall St.
Sep-02-20 04:05PM	Aeglea BioTherapeutics to Participate in September Investment Conferences GlobeNewswire
Aug-25-20 08:40AM	Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session Zacks
Aug-18-20 04:05PM	Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020 GlobeNewswire
Aug-10-20 08:30AM	Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights GlobeNewswire
Jul-13-20 09:28AM	How Should Investors React To Aeglea BioTherapeutics' (NASDAQ:AGLE) CEO Pay? Simply Wall St. -5.31%
Jun-30-20 11:25PM	Were Hedge Funds Right About Buying Aeglea BioTherapeutics, Inc. (AGLE)? Insider Monkey
Jun-29-20 12:00PM	Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE) Zacks
Jun-26-20 11:30AM	Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year? Zacks -6.40%
Jun-23-20 08:47AM	Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1% Zacks -11.37%
Jun-10-20 11:30AM	Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year? Zacks
Jun-08-20 09:03AM	Why Aeglea BioTherapeutics (AGLE) Stock Might be a Great Pick Zacks
Jun-04-20 11:17AM	Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio Zacks
Jun-01-20 04:05PM	Aeglea BioTherapeutics to Present at BIO Digital 2020 GlobeNewswire
May-29-20 11:49AM	Aeglea BioTherapeutics' Shares March Higher, Can It Continue? Zacks
May-28-20 04:10PM	Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020 GlobeNewswire
May-27-20 08:43AM	Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1% Zacks
May-26-20 08:30AM	Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology GlobeNewswire
May-21-20 11:30AM	Is Aeglea BioTherapeutics (AGLE) Outperforming Other Medical Stocks This Year? Zacks
May-20-20 08:56AM	Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources Zacks
May-19-20 07:26PM	Find Strong Stocks During the Coronavirus with New Analyst Coverage Zacks +7.82%
10:10AM	4 Stocks in the Limelight on New Analyst Coverage Zacks
08:30AM	Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology GlobeNewswire
May-07-20 08:41AM	Is Aeglea BioTherapeutics (AGLE) Stock a Solid Choice Right Now? Zacks +5.50%
08:30AM	Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights GlobeNewswire
May-06-20 09:31AM	Aeglea BioTherapeutics, Inc. (AGLE) Shares March Higher, Can It Continue? Zacks -7.90%
06:19AM	Anthony Quinn Is The President of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) And They Just Picked Up 44% More Shares Simply Wall St.
May-05-20 12:00PM	Aeglea (AGLE) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Apr-30-20 04:05PM	Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-28-20 09:07AM	Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering GlobeNewswire +28.02%
Apr-27-20 04:01PM	Aeglea BioTherapeutics Announces Proposed Public Offering GlobeNewswire
Apr-08-20 07:30AM	Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177) GlobeNewswire +7.42%
Mar-29-20 08:31AM	Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Particularly Volatile Share Price? Simply Wall St.
Feb-24-20 07:30AM	Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones GlobeNewswire -5.72%
Feb-13-20 05:37AM	Should Aeglea BioTherapeutics (NASDAQ:AGLE) Be Disappointed With Their 66% Profit? Simply Wall St.
Jan-13-20 07:00AM	Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177) GlobeNewswire
Jan-08-20 05:11AM	Is Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) CEO Salary Justified? Simply Wall St.
Jan-06-20 04:05PM	Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-12-19 07:08PM	Hedge Funds Are Dumping Aeglea BioTherapeutics, Inc. (AGLE) Insider Monkey
Dec-03-19 05:22AM	Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Increased Their Holdings Simply Wall St.
Nov-26-19 08:30AM	Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-06-19 08:30AM	Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights GlobeNewswire
Nov-04-19 08:30AM	Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer GlobeNewswire
Oct-10-19 08:54AM	Will Aeglea BioTherapeutics (NASDAQ:AGLE) Spend Its Cash Wisely? Simply Wall St.
Sep-04-19 11:22AM	Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Volatile Share Price? Simply Wall St.
Sep-03-19 06:00AM	Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium GlobeNewswire
Aug-29-19 08:30AM	Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium GlobeNewswire
Aug-06-19 08:00AM	Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights GlobeNewswire
Jul-25-19 07:21AM	The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug Benzinga +19.58%
Jul-24-19 04:05PM	Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency GlobeNewswire
Jul-17-19 03:47PM	Can We See Significant Institutional Ownership On The Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Share Register? Simply Wall St.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes cystinuria and research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shanafelt Armen	Director	Dec 13	Buy	3.65	14,685	53,600	150,000	Dec 13 08:41 PM
Shanafelt Armen	Director	Dec 10	Buy	3.65	13,516	49,333	135,315	Dec 13 08:41 PM
Quinn Anthony G.	President & CEO	Dec 10	Buy	3.75	10,526	39,472	328,795	Dec 13 08:39 PM
Shanafelt Armen	Director	Dec 09	Buy	3.67	121,799	446,759	121,799	Dec 13 08:41 PM
Quinn Anthony G.	President & CEO	Dec 09	Buy	3.70	43,108	159,500	318,269	Dec 13 08:39 PM
Alspaugh Jonathan	Chief Financial Officer	Dec 09	Buy	3.72	50,000	186,000	90,372	Dec 13 08:37 PM
Alspaugh Jonathan	Chief Financial Officer	Aug 18	Buy	6.72	7,200	48,400	40,372	Aug 18 05:21 PM
Alspaugh Jonathan	Chief Financial Officer	Aug 17	Buy	6.50	23,392	151,985	33,172	Aug 18 05:21 PM
Alspaugh Jonathan	Chief Financial Officer	Aug 16	Buy	6.37	9,780	62,275	9,780	Aug 18 05:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience